February 13 2026 update: A regulatory focused review of a post viral autonomic study that lists POTS and autonomic dysfunction among conditions. The trial notes Blood Sample Collection as an intervention and is sponsored by Brigham and Women’s Hospital and FBRI LLC (F Prime Capital). The project is active and not currently recruiting. This report outlines what is known about the study and the implications for medical device developers and regulators based on the source ClinicalTrials.gov record NCT07405515 and related documentation.
What is the focus of this study
The ClinicalTrials.gov entry for NCT07405515 references conditions including post viral autonomic dysfunction and Postural Tachycardia Syndrome. The label POTS denotes an autonomic disorder characterized by a rapid heart rate after standing and related symptoms. The listing under Interventions notes Blood Sample Collection as a component of the protocol. The labeling and search terms indicate a medical device oriented approach to study design, with emphasis on measuring biological or functional endpoints that may be used to support device related hypotheses. The sponsor information lists Brigham and Women’s Hospital together with FBRI LLC, a venture affiliated sponsor connected to F Prime Capital. The entry is described as active but not recruiting at the time of the record. Regulators should interpret these details as a description of a device minded program and consider the implications for device labeling, performance claims and safety documentation.
What endpoints or outcomes are described
Specific numeric endpoints are not disclosed in the provided source text. The record emphasizes a general focus on autonomic function and biomarker collection via blood samples. In a device oriented context endpoints may relate to safety measures and data quality rather than direct patient outcomes. Regulators should look for a clear intended use and performance claims in the device submission if such data is generated.
Who is affected by post viral autonomic dysfunction and POTS
Post viral disorders and COVID 19 have been associated with autonomic nervous system dysfunction in a subset of patients. POTS is a form of dysautonomia where upright posture triggers a rapid heart rate with symptoms such as lightheadedness fatigue headaches and brain fog. The data collection context indicates that researchers seek to understand the pathophysiology of these conditions and the potential role a device oriented approach may play in diagnostics or biomarker assessment. Understanding the patient population helps device developers and regulators discuss the scope of intended use and risk management for future products.
What does the regulatory frame imply for device makers
In the MDR environment the intended purpose of a device must be clearly defined with evidence of performance and safety. If the trial involves a device based approach to collecting or analyzing blood samples data must be collected under robust privacy and consent rules. Labeling must reflect capabilities and limitations and post market oversight needs must be addressed. Even when a trial is described as active and not recruiting it signals regulatory interest in the approach to autonomic function assessment. This article does not provide device specific claims but frames the topic for regulators and manufacturers evaluating future submissions.
Who sponsors this work and how is data handled
The study is sponsored by Brigham and Women’s Hospital and FBRI LLC (F Prime Capital). The collaboration between a major hospital and a venture group signals industry engagement in research on autonomic dysfunction and post viral conditions. Data handling and privacy for blood samples are key aspects that regulators will review. The record does not present patient outcomes and remains a description of an exploratory program rather than a definitive clinical result. Device developers should monitor for updates on data governance and consent frameworks as the project progresses.
Frequently asked questions
- Question 1 What is the scope of the study
- Question 2 Are there safety concerns for participants
- Question 3 How will data be used to support device oriented hypotheses
- Question 4 When can results be expected
In summary this regulatory oriented update notes a study focusing on autonomic dysfunction and POTS in post viral syndromes including COVID 19. Key takeaways for regulators and device developers include ensuring a well defined intended use clear safety data and robust privacy controls. Stakeholders should monitor the ClinicalTrials.gov entry for future disclosure of endpoints and device related performance data.
Disclaimer This article is intended for medical device professionals It is not legal advice Interpretations should be verified with regulatory counsel and the official MDR guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07405515?term=medical+device